Business Wire

CT-WELLAIR

23.3.2022 07:35:03 CET | Business Wire | Press release

Share
WellAir Launches a New Advanced Air Cleaning Device in Europe with Independently Tested Industry Leading 99.9% Effectiveness Against Airborne Pathogens

WellAir, the leading health technology company that provides indoor air disinfection solutions, today announced the European launch of its Novaerus Defend 400. Novaerus has been a pioneer in combatting airborne and surface transmitted hospital-acquired infections world-wide for over 10 years. The air cleaning device is CE marked and is 99.9% effective at inactivating airborne pathogens such as SARS-CoV-2 proxy virus (MS2 Bacteriophage), MRSA, bacteria, and fungi; while also purifying the air of particulate matter, volatile organic compounds, gases, and odours. With the launch, WellAir continues to chart a new path forward for healthy indoor environments at a time when air quality has never been a bigger priority.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322005036/en/

Recent research published in the Journal of Hospital Infectionalso found that Novaerus air disinfection devices utilizing NanoStrike technology - a transformational method of air disinfection that bursts airborne pathogen cells, rapidly inactivating them to help ensure they are no longer a threat of infection - may contribute to the prevention of hospital-acquired infections by reducing the microbial load in the air. The study is the first of its kind to examine portable air cleaning and disinfection devices in an intensive care unit.

“We are bringing the Defend 400 to the European market at a turning point for indoor air quality, as more people are recognizing the role it plays in health and wellness,” said WellAir Chief Science Officer Felipe Soberon. “Given that much of this technology was developed in Dublin laboratories, it is great to see this technology now available in Europe, following a successful U.S. launch.”

Unlike other air cleaning technologies, NanoStrike’s effectiveness lies in its ability to inactivate nanosized pathogens on contact. The Defend 400’s four-stage pathogen inactivation and filtration process also utilizes medical-grade filters in order to capture bacterial debris, fine and large particles, VOCs, gases, odours, and impurities.

“COVID-19 has focused more attention on indoor air quality and has elevated the importance of safer indoor environments by reducing the risk of exposure to airborne pathogens. This is exactly what the Defend 400 is designed to do”, said WellAir President and CEO Todd M. Pope. “This portable device expands our product portfolio, delivering powerful air cleaning in multiple device sizes.”

The Novaerus Defend 400 is ideally suited for healthcare settings but is effective in a wide array of indoor environments, such as schools and offices. It is available through WellAir’s Novaerus global distributor network. For more information, visit: https://www.novaerus.com/novaerus-defend-400.

About WellAir

WellAir’s mission is to make the indoor world cleaner and safer. The company’s broad range of clean air and surface products are scientifically proven to help safeguard how people work, live and play. WellAir, headquartered in Dublin, Ireland, with offices in Research Triangle Park, North Carolina, and Stamford, Connecticut, is a leading provider of infection control solutions.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SES Announces Extraordinary General Meeting of Shareholders15.5.2026 08:30:00 CEST | Press release

SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun

Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 08:00:00 CEST | Press release

New global long‑term partnership embeds Experian’s Ascend capabilities directly into ServiceNow workflows, transforming client operations Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership e

Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 03:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c

Boomi Teams up With Gong to Bring Revenue AI to Boomi Agentstudio14.5.2026 18:00:00 CEST | Press release

Gong's revenue AI is now natively available in the Boomi Enterprise Platform Boomi, the data activation company for AI, today announced a collaboration withGong, the leader in Revenue AI, to bring revenue signals captured in Gong natively into the Boomi Enterprise Platform. This collaboration enables enterprises to establish an active data foundation designed to transform customer conversations into coordinated, automated actions across systems and functions enterprise-wide with Boomi Agentstudio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514443012/en/ Boomi Teams Up with Gong to Bring Revenue AI to Boomi Agentstudio Gong goes beyond capturing deal activity to surface real-time insights into risk, buyer intent, competitive dynamics, and key engagement signals. That intelligence moves from conversation to coordinated action, flowing across CRM, ERP, product, and operational systems with the governance and security tha

Xsolla and Skich Announce Strategic Partnership to Bring Merchant of Record Payments to an Alternative Mobile Game Marketplace14.5.2026 18:00:00 CEST | Press release

Partnership Enables Developers To Monetize Games On The Skich Store With Xsolla Handling Payments, Tax Compliance, And Commerce Infrastructure Xsolla, a leading global video game commerce company, today announced a strategic partnership with Skich, an alternative mobile game marketplace operating on iOS in the EU under Apple's Digital Markets Act provisions and on Android globally. Under the agreement, Xsolla will serve as Merchant of Record for in-app purchases and paid game sales distributed through the Skich Store. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514867730/en/ Graphic: Xsolla Skich serves as an alternative to traditional mobile storefronts, offering developers a way to reach players outside platform-controlled distribution channels. The partnership with Xsolla enables Skich to offer a fully compliant payment and commerce layer, with Xsolla managing payment processing, tax collection, refunds, and regulat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye